Donepezil
- TRADE NAMES: Aricept (Eisai); Aricept Evess (Eisai)
- INDICATIONS: Mild, moderate and severe dementia of the Alzheimer’s type
- CLASS: Acetylcholinesterase inhibitor, Cholinesterase inhibitor, Parasympathomimetic
- HALF-LIFE: 50–70 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticholinergics, Cholinergic agonists, Galantamine, Non-depolarising muscle relaxants, Ramelteon, Succinylcholine
PREGNANCY CATEGORY: C
Contra-indicated in patients with known hypersensitivity to donepezil hydrochloride or
to piperidine derivatives.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of donepezil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/28/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric